LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Отворен

15.41 3.42

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.78

Максимум

15.58

Ключови измерители
By Trading Economics
Приходи	-6.4M -20M
Продажби	-807K 71M
EPS	-0.13
Марж на печалбата	-28.24
Служители	624
EBITDA	-7.9M -14M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+45.74% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-95M 2.2B
Предишно отваряне	11.99
Предишно затваряне	15.41

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.05.2026 г., 22:47 ч. UTC

Печалби

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28.05.2026 г., 20:45 ч. UTC

Печалби

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28.05.2026 г., 23:31 ч. UTC

Пазарно говорене

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28.05.2026 г., 23:02 ч. UTC

Пазарно говорене

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28.05.2026 г., 22:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.05.2026 г., 22:41 ч. UTC

Пазарно говорене

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28.05.2026 г., 22:37 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

M&A-Related Insurance Payments In North America Rise -- Market Talk

28.05.2026 г., 22:04 ч. UTC

Придобивния, сливания и поглъщания

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28.05.2026 г., 22:04 ч. UTC

Придобивния, сливания и поглъщания

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28.05.2026 г., 21:12 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28.05.2026 г., 21:00 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28.05.2026 г., 20:57 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings -- Barrons.com

28.05.2026 г., 20:55 ч. UTC

Печалби

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

28.05.2026 г., 20:48 ч. UTC

Горещи акции

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28.05.2026 г., 20:34 ч. UTC

Печалби

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28.05.2026 г., 20:31 ч. UTC

Печалби

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28.05.2026 г., 20:28 ч. UTC

Печалби

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28.05.2026 г., 20:26 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings -- Barrons.com

28.05.2026 г., 20:20 ч. UTC

Печалби

Costco 3Q Membership Fees $1.37B

28.05.2026 г., 20:20 ч. UTC

Печалби

Costco 3Q Net Sales $69.15B

28.05.2026 г., 20:19 ч. UTC

Печалби

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28.05.2026 г., 20:19 ч. UTC

Печалби

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28.05.2026 г., 20:17 ч. UTC

Печалби

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28.05.2026 г., 20:17 ч. UTC

Печалби

Costco 3Q Same-Store Sales Up 9.8% >COST

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

45.74% нагоре

12-месечна прогноза

Среден 20.17 USD 45.74%

Висок 22 USD

Нисък 18 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.